• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023

    8/31/23 11:00:30 AM ET
    $ANET
    $CHRD
    $CHRW
    $CHWY
    Computer Communications Equipment
    Telecommunications
    Oil & Gas Production
    Energy
    Get the next $ANET alert in real time by email

    Upgrades

    Jefferies upgraded the previous rating for Mesoblast Ltd (NASDAQ:MESO) from Hold to Buy. NoneThe current stock performance of Mesoblast shows a 52-week-high of $5.12 and a 52-week-low of $1.16. Moreover, at the end of the last trading period, the closing price was at $1.43.

    Argus Research upgraded the previous rating for Oshkosh Corp (NYSE:OSK) from Hold to Buy. For the second quarter, Oshkosh had an EPS of $2.69, compared to year-ago quarter EPS of $0.41. The stock has a 52-week-high of $106.66 and a 52-week-low of $69.31. At the end of the last trading period, Oshkosh closed at $103.23.

    Evercore ISI Group upgraded the previous rating for Okta Inc (NASDAQ:OKTA) from Underperform to In-Line. For the second quarter, Okta had an EPS of $0.31, compared to year-ago quarter EPS of $0.10. The stock has a 52-week-high of $94.64 and a 52-week-low of $44.13. At the end of the last trading period, Okta closed at $73.57.

    For Shopify Inc (NYSE:SHOP), Canaccord Genuity upgraded the previous rating of Hold to Buy. Shopify earned $0.14 in the second quarter, compared to $0.03 in the year-ago quarter. The current stock performance of Shopify shows a 52-week-high of $71.43 and a 52-week-low of $23.64. Moreover, at the end of the last trading period, the closing price was at $60.01.

    BMO Capital upgraded the previous rating for The Hanover Insurance Group Inc (NYSE:THG) from Market Perform to Outperform. Hanover Insurance Gr earned $1.91 in the second quarter, compared to $2.32 in the year-ago quarter. The stock has a 52-week-high of $148.78 and a 52-week-low of $103.90. At the end of the last trading period, Hanover Insurance Gr closed at $106.00.

    Citigroup upgraded the previous rating for Arista Networks Inc (NYSE:ANET) from Neutral to Buy. In the second quarter, Arista Networks showed an EPS of $1.58, compared to $1.08 from the year-ago quarter. At the moment, the stock has a 52-week-high of $193.91 and a 52-week-low of $98.72. Arista Networks closed at $187.10 at the end of the last trading period.

    For Guidewire Software Inc (NYSE:GWRE), Wells Fargo upgraded the previous rating of Underweight to Equal-Weight. For the third quarter, Guidewire Software had an EPS of $0.08, compared to year-ago quarter EPS of $0.26. At the moment, the stock has a 52-week-high of $86.79 and a 52-week-low of $52.19. Guidewire Software closed at $83.80 at the end of the last trading period.

    Redburn Partners upgraded the previous rating for Exxon Mobil Corp (NYSE:XOM) from Sell to Neutral. Exxon Mobil earned $1.94 in the second quarter, compared to $4.14 in the year-ago quarter. At the moment, the stock has a 52-week-high of $119.92 and a 52-week-low of $83.89. Exxon Mobil closed at $110.88 at the end of the last trading period.

    According to Raymond James, the prior rating for SkyWest Inc (NASDAQ:SKYW) was changed from Market Perform to Outperform. In the second quarter, SkyWest showed an EPS of $0.35, compared to $1.07 from the year-ago quarter. The current stock performance of SkyWest shows a 52-week-high of $45.98 and a 52-week-low of $14.76. Moreover, at the end of the last trading period, the closing price was at $41.40.

    For 3M Co (NYSE:MMM), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. 3M earned $2.17 in the second quarter, compared to $2.48 in the year-ago quarter. The current stock performance of 3M shows a 52-week-high of $133.89 and a 52-week-low of $92.38. Moreover, at the end of the last trading period, the closing price was at $104.45.

    JP Morgan upgraded the previous rating for Vasta Platform Ltd (NASDAQ:VSTA) from Neutral to Overweight. Vasta Platform earned $0.20 in the second quarter, compared to $0.18 in the year-ago quarter. The current stock performance of Vasta Platform shows a 52-week-high of $5.60 and a 52-week-low of $3.05. Moreover, at the end of the last trading period, the closing price was at $3.66.

    See all analyst ratings upgrades.

    Downgrades

    Chardan Capital downgraded the previous rating for Outlook Therapeutics Inc (NASDAQ:OTLK) from Buy to Neutral. For the third quarter, Outlook Therapeutics had an EPS of $0.08, compared to year-ago quarter EPS of $0.08. The current stock performance of Outlook Therapeutics shows a 52-week-high of $2.03 and a 52-week-low of $0.21. Moreover, at the end of the last trading period, the closing price was at $0.27.

    Oppenheimer downgraded the previous rating for Dollar General Corp (NYSE:DG) from Outperform to Perform. In the second quarter, Dollar Gen showed an EPS of $2.13, compared to $2.98 from the year-ago quarter. The stock has a 52-week-high of $261.57 and a 52-week-low of $151.27. At the end of the last trading period, Dollar Gen closed at $157.66.

    Susquehanna downgraded the previous rating for C.H. Robinson Worldwide Inc (NASDAQ:CHRW) from Neutral to Negative. In the second quarter, C.H. Robinson Worldwide showed an EPS of $0.90, compared to $2.52 from the year-ago quarter. The stock has a 52-week-high of $116.76 and a 52-week-low of $86.63. At the end of the last trading period, C.H. Robinson Worldwide closed at $94.63.

    Susquehanna downgraded the previous rating for RXO Inc (NYSE:RXO) from Neutral to Negative. In the second quarter, RXO showed an EPS of $0.08, compared to $0.56 from the year-ago quarter. At the moment, the stock has a 52-week-high of $23.74 and a 52-week-low of $14.75. RXO closed at $18.81 at the end of the last trading period.

    For Outlook Therapeutics Inc (NASDAQ:OTLK), HC Wainwright & Co. downgraded the previous rating of Buy to Neutral. In the third quarter, Outlook Therapeutics showed an EPS of $0.08, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $2.03 and a 52-week-low of $0.21. At the end of the last trading period, Outlook Therapeutics closed at $0.27.

    According to Wells Fargo, the prior rating for Victoria's Secret & Co (NYSE:VSCO) was changed from Overweight to Equal-Weight. In the second quarter, Victoria's Secret showed an EPS of $0.24, compared to $1.09 from the year-ago quarter. The current stock performance of Victoria's Secret shows a 52-week-high of $48.12 and a 52-week-low of $16.78. Moreover, at the end of the last trading period, the closing price was at $17.94.

    Evercore ISI Group downgraded the previous rating for Chewy Inc (NYSE:CHWY) from Outperform to In-Line. In the second quarter, Chewy showed an EPS of $0.15, compared to $0.05 from the year-ago quarter. The current stock performance of Chewy shows a 52-week-high of $52.88 and a 52-week-low of $25.29. Moreover, at the end of the last trading period, the closing price was at $27.33.

    CLSA downgraded the previous rating for Gaotu Techedu Inc (NYSE:GOTU) from Outperform to Underperform. Gaotu Techedu earned $0.03 in the second quarter, compared to $0.00 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.49 and a 52-week-low of $0.64. Gaotu Techedu closed at $3.24 at the end of the last trading period.

    JP Morgan downgraded the previous rating for Hostess Brands Inc (NASDAQ:TWNK) from Overweight to Neutral. Hostess Brands earned $0.28 in the second quarter, compared to $0.22 in the year-ago quarter. The stock has a 52-week-high of $28.97 and a 52-week-low of $21.59. At the end of the last trading period, Hostess Brands closed at $28.06.

    For Medical Properties Trust Inc (NYSE:MPW), Mizuho downgraded the previous rating of Buy to Neutral. In the second quarter, Medical Properties Trust showed an EPS of $0.48, compared to $0.46 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.15 and a 52-week-low of $6.38. Medical Properties Trust closed at $7.34 at the end of the last trading period.

    Morgan Stanley downgraded the previous rating for Palantir Technologies Inc (NYSE:PLTR) from Equal-Weight to Underweight. Palantir Technologies earned $0.05 in the second quarter, compared to $0.01 in the year-ago quarter. The current stock performance of Palantir Technologies shows a 52-week-high of $20.24 and a 52-week-low of $5.84. Moreover, at the end of the last trading period, the closing price was at $16.33.

    According to B. Riley Securities, the prior rating for MasterCraft Boat Holdings Inc (NASDAQ:MCFT) was changed from Buy to Neutral. In the fourth quarter, MasterCraft Boat Hldgs showed an EPS of $1.37, compared to $1.92 from the year-ago quarter. The current stock performance of MasterCraft Boat Hldgs shows a 52-week-high of $35.29 and a 52-week-low of $18.49. Moreover, at the end of the last trading period, the closing price was at $21.76.

    See all analyst ratings downgrades.

    Initiations

    Raymond James initiated coverage on Middlefield Banc Corp (NASDAQ:MBCN) with a Market Perform rating. For the second quarter, Middlefield Banc had an EPS of $0.63, compared to year-ago quarter EPS of $0.70. The stock has a 52-week-high of $30.21 and a 52-week-low of $22.09. At the end of the last trading period, Middlefield Banc closed at $26.99.

    Raymond James initiated coverage on Flushing Financial Corp (NASDAQ:FFIC) with an Outperform rating. The price target for Flushing Financial is set to $17.00. In the second quarter, Flushing Financial showed an EPS of $0.26, compared to $0.70 from the year-ago quarter. The current stock performance of Flushing Financial shows a 52-week-high of $21.55 and a 52-week-low of $9.28. Moreover, at the end of the last trading period, the closing price was at $14.04.

    With an Outperform rating, Raymond James initiated coverage on Plumas Bancorp (NASDAQ:PLBC). The price target seems to have been set at $38.00 for Plumas. In the second quarter, Plumas showed an EPS of $1.12, compared to $0.96 from the year-ago quarter. The stock has a 52-week-high of $45.31 and a 52-week-low of $27.50. At the end of the last trading period, Plumas closed at $34.71.

    With a Buy rating, Truist Securities initiated coverage on RadNet Inc (NASDAQ:RDNT). The price target seems to have been set at $40.00 for RadNet. For the second quarter, RadNet had an EPS of $0.24, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $35.18 and a 52-week-low of $12.14. At the end of the last trading period, RadNet closed at $33.01.

    Janney Montgomery Scott initiated coverage on Microvast Holdings Inc (NASDAQ:MVST) with a Buy rating. The price target for Microvast Holdings is set to $8.00. For the second quarter, Microvast Holdings had an EPS of $0.02, compared to year-ago quarter EPS of $0.05. At the moment, the stock has a 52-week-high of $2.91 and a 52-week-low of $0.88. Microvast Holdings closed at $1.81 at the end of the last trading period.

    BMO Capital initiated coverage on Civitas Resources Inc (NYSE:CIVI) with an Outperform rating. The price target for Civitas Resources is set to $95.00. Civitas Resources earned $1.72 in the second quarter, compared to $4.63 in the year-ago quarter. The stock has a 52-week-high of $81.63 and a 52-week-low of $52.77. At the end of the last trading period, Civitas Resources closed at $81.28.

    BMO Capital initiated coverage on Chord Energy Corp (NASDAQ:CHRD) with an Outperform rating. The price target for Chord Energy is set to $185.00. In the second quarter, Chord Energy showed an EPS of $3.65, compared to $7.30 from the year-ago quarter. At the moment, the stock has a 52-week-high of $164.79 and a 52-week-low of $117.05. Chord Energy closed at $158.66 at the end of the last trading period.

    HC Wainwright & Co. initiated coverage on Lyra Therapeutics Inc (NASDAQ:LYRA) with a Buy rating. The price target for Lyra Therapeutics is set to $12.00. In the second quarter, Lyra Therapeutics showed an EPS of $0.36, compared to $0.43 from the year-ago quarter. The current stock performance of Lyra Therapeutics shows a 52-week-high of $6.37 and a 52-week-low of $1.86. Moreover, at the end of the last trading period, the closing price was at $3.36.

    With a Buy rating, Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX). The price target seems to have been set at $76.00 for MoonLake. For the second quarter, MoonLake had an EPS of $0.23, compared to year-ago quarter EPS of $0.34. The stock has a 52-week-high of $63.40 and a 52-week-low of $7.05. At the end of the last trading period, MoonLake closed at $56.19.

    With an Overweight rating, JP Morgan initiated coverage on MP Materials Corp (NYSE:MP). The price target seems to have been set at $27.00 for MP Materials. In the second quarter, MP Materials showed an EPS of $0.09, compared to $0.41 from the year-ago quarter. The current stock performance of MP Materials shows a 52-week-high of $36.67 and a 52-week-low of $19.18. Moreover, at the end of the last trading period, the closing price was at $20.33.

    JP Morgan initiated coverage on Establishment Labs Holdings Inc (NASDAQ:ESTA) with an Overweight rating. The price target for Establishment Labs Hldgs is set to $75.00. In the second quarter, Establishment Labs Hldgs showed an EPS of $0.65, compared to $1.52 from the year-ago quarter. At the moment, the stock has a 52-week-high of $79.88 and a 52-week-low of $44.48. Establishment Labs Hldgs closed at $58.09 at the end of the last trading period.

    With an Outperform rating, Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). The price target seems to have been set at $40.00 for Crinetics Pharmaceuticals. In the second quarter, Crinetics Pharmaceuticals showed an EPS of $0.94, compared to $0.81 from the year-ago quarter. The current stock performance of Crinetics Pharmaceuticals shows a 52-week-high of $24.58 and a 52-week-low of $15.23. Moreover, at the end of the last trading period, the closing price was at $16.52.

    See all analyst ratings initiations.

    Get the next $ANET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANET
    $CHRD
    $CHRW
    $CHWY

    CompanyDatePrice TargetRatingAnalyst
    Shopify Inc.
    $SHOP
    2/10/2026$150.00Neutral → Buy
    MoffettNathanson
    Palantir Technologies Inc.
    $PLTR
    2/10/2026$180.00Neutral → Buy
    Daiwa Securities
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$205.00Hold → Buy
    HSBC Securities
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$190.00Market Perform → Outperform
    Northland Capital
    Exxon Mobil Corporation
    $XOM
    2/3/2026$125.00Neutral → Underperform
    BNP Paribas Exane
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$200.00Neutral → Outperform
    Robert W. Baird
    Oshkosh Corporation (Holding Company)
    $OSK
    2/3/2026$149.00Underperform → Neutral
    BofA Securities
    Exxon Mobil Corporation
    $XOM
    2/3/2026$135.00 → $145.00Buy
    TD Cowen
    More analyst ratings

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Shopify upgraded by MoffettNathanson with a new price target

    MoffettNathanson upgraded Shopify from Neutral to Buy and set a new price target of $150.00

    2/10/26 7:58:08 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Palantir Technologies upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Palantir Technologies from Neutral to Buy and set a new price target of $180.00

    2/10/26 7:57:53 AM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    Palantir Technologies upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Palantir Technologies from Hold to Buy and set a new price target of $205.00

    2/3/26 12:10:56 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Coliseum Capital Management, Llc bought $2,649,367 worth of shares (134,807 units at $19.65) (SEC Form 4)

    4 - MasterCraft Boat Holdings, Inc. (0001638290) (Issuer)

    12/22/25 7:54:39 PM ET
    $MCFT
    Marine Transportation
    Industrials

    Director Cooper Troy A. bought $88,243 worth of shares (8,317 units at $10.61), increasing direct ownership by 3% to 275,416 units (SEC Form 4)

    4 - RXO, Inc. (0001929561) (Issuer)

    11/24/25 8:00:06 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Amendment: Director Kingshott Adrian bought $100,512 worth of shares (9,350 units at $10.75), increasing direct ownership by 11% to 91,137 units (SEC Form 4)

    4/A - RXO, Inc. (0001929561) (Issuer)

    11/19/25 4:15:39 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    $ANET
    $CHRD
    $CHRW
    $CHWY
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    2/11/26 5:00:40 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Chord Energy Corporation

    SCHEDULE 13G/A - Chord Energy Corp (0001486159) (Subject)

    2/11/26 1:40:18 PM ET
    $CHRD
    Oil & Gas Production
    Energy

    SEC Form 10-K filed by Shopify Inc.

    10-K - SHOPIFY INC. (0001594805) (Filer)

    2/11/26 7:03:35 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah. The study results showed that Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease (SR-aGvHD) irrespective whether used in children or adults, as second or third line, and in ruxolitinib naive or resistant patients.1 Ryoncil® is the

    2/11/26 6:27:47 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RXO Prices $400 Million Senior Notes Offering

    RXO, Inc. (NYSE:RXO) (the "Company") today announced that it has priced its offering of $400 million aggregate principal amount of 6.375% Senior Notes due 2031 (the "2031 Notes"). The 2031 Notes will initially be guaranteed on a senior unsecured basis by the domestic subsidiaries of the Company that are guarantors under the Company's asset-based revolving credit facility. The Company intends to use the net proceeds from the offering of the 2031 Notes to repurchase or redeem all of the Company's outstanding 7.500% Notes due 2027, to pay related fees and expenses and for general corporate purposes, which may include repayment of indebtedness. This press release shall not constitute an offer

    2/11/26 5:41:00 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

    ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) following receipt of a Complete Response Letter (CRL) dated December 30, 2025, regarding the Company's Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). The CRL identified a single deficiency based on a purported lack of substantial evidence of effectiveness, and recommended

    2/11/26 8:45:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANET
    $CHRD
    $CHRW
    $CHWY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 14, 2023 - FDA Warns Nine Manufacturers, Distributors of Unapproved Antimicrobials for Animals

    For Immediate Release: December 14, 2023 Today, the U.S. Food and Drug Administration is announcing the issuance of nine warning letters to manufacturers and distributors of unapproved and misbranded antimicrobial animal drugs for violations of federal law. The agency is concerned because these products contain antimicrobials that are important in human medicine and using them without medical oversight contribut

    12/14/23 9:00:20 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    January 22, 2021 - Coronavirus (COVID-19) Update: January 22, 2021

    For Immediate Release: January 22, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found th

    1/22/21 3:54:10 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHRO and ESG Officer Freeman Angela K. covered exercise/tax liability with 5,926 shares and sold $1,720,261 worth of shares (8,579 units at $200.52), decreasing direct ownership by 21% to 55,611 units (SEC Form 4)

    4 - C. H. ROBINSON WORLDWIDE, INC. (0001043277) (Issuer)

    2/11/26 6:02:02 PM ET
    $CHRW
    Integrated Freight & Logistics
    Industrials

    President, Global Forwarding Short Michael John covered exercise/tax liability with 3,787 shares and sold $1,281,878 worth of shares (6,368 units at $201.30), decreasing direct ownership by 16% to 52,101 units (SEC Form 4)

    4 - C. H. ROBINSON WORLDWIDE, INC. (0001043277) (Issuer)

    2/11/26 6:01:26 PM ET
    $CHRW
    Integrated Freight & Logistics
    Industrials

    Director Robison Kenneth Edward Iii sold $24,670 worth of shares (500 units at $49.34) (SEC Form 4)

    4 - PLUMAS BANCORP (0001168455) (Issuer)

    2/10/26 6:36:21 PM ET
    $PLBC
    Finance Companies
    Finance

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Leadership Updates

    Live Leadership Updates

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Critical Minerals Take Center Stage as U.S. Accelerates Push for Domestic Supply Security

    NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Western world is entering a strategic race to secure domestic supplies of critical minerals, creating a compelling opportunity set for investors focused on resource security and long-term value for active miners that include Military Metals Corp. (OTCQB:MILIF) (CSE:MILI), Perpetua Resources Corp. (NASDAQ:PPTA) (TSX:PPTA), United States Antimony Corporation (NYSE:UAMY), MP Materials Corp. (NYSE:MP), Critical Metals Corp. (NASDAQ:CRML). Antimony and gold are moving to the forefront as strategically vital materials: antimony for defense systems, semiconductors, and advanced energy applications, and gold for financial stability, electronics, and

    1/7/26 8:45:00 AM ET
    $CRML
    $MP
    $PPTA
    Metal Mining
    Basic Materials
    Precious Metals
    Metal Fabrications

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Financials

    Live finance-specific insights

    View All

    Shopify's Standout 2025: The Launchpad for a New Era of Commerce in 2026

    $11.6B in revenue, $2B in free cash flow and the launch of a $2B share repurchase programInternet, Everywhere--(Newsfile Corp. - February 11, 2026) - Shopify Inc. ((NASDAQ, TSX:SHOP) announced today financial results for the quarter and year ended December 31, 2025. Shopify achieved Q4 revenue growth of 31% and a 19% free cash flow margin, marking ten consecutive quarters of double-digit free cash flow margins."2025 was Shopify at full throttle - driving compounding growth, while laying the rails for the new era of AI commerce," said Harley Finkelstein, President of Shopify. "2026 will be the year of the builders, and we'll be powering them - from first sale to full scale."Jeff Hoffmeister,

    2/11/26 7:00:00 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Chord Energy Schedules Fourth Quarter and Year-End 2025 Earnings Release and Conference Call

    HOUSTON, Feb. 10, 2026 /PRNewswire/ -- Chord Energy Corp. (NASDAQ:CHRD) ("Chord" or the "Company") plans to announce its fourth quarter and year-end 2025 financial and operating results on Wednesday, February 25, 2026 after market close. The Company will host a live webcast and conference call on Thursday, February 26, 2026 at 10:00 a.m. Central. Investors, analysts and other interested parties are invited to listen to the webcast: Date: Thursday, February 26, 2026 Time: 10:00 a.m. Central Live Webcast: https://app.webinar.net/mBbx0VZ0w4o You may use the following dial-in info

    2/10/26 4:05:00 PM ET
    $CHRD
    Oil & Gas Production
    Energy

    Middlefield Banc Corp. Reports 2025 Twelve-Month Financial Results

    MIDDLEFIELD, Ohio, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ:MBCN) today reported financial results for the twelve months ended December 31, 2025. Ronald L. Zimmerly, Jr., President and Chief Executive Officer, stated, "2025 was a strong year of operating and financial growth for Middlefield, driven by consistent execution and continued momentum across the Bank. We are pleased with the progress we've made and are focused on completing our merger with Farmers National Banc Corp., which we expect to close in the first quarter of 2026. We believe this combination will create meaningful opportunities for our customers, employees, and shareholders." Income StatementNet

    2/10/26 4:05:00 PM ET
    $MBCN
    Major Banks
    Finance

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by MP Materials Corp.

    SC 13D/A - MP Materials Corp. / DE (0001801368) (Subject)

    12/4/24 7:57:02 PM ET
    $MP
    Metal Mining
    Basic Materials

    $ANET
    $CHRD
    $CHRW
    $CHWY
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Exxon Mobil Corporation on Jun 20

    Director Dreyfus Maria S. bought $2,000,386 worth of shares (18,310 units at $109.25), increasing direct ownership by 105% to 35,757 units (SEC Form 4) on June 20, 2024. This substantial insider purchase is a significant development for Exxon Mobil Corporation. As we delve into the recent insider activity at Exxon Mobil, we notice a few interesting patterns. Prior to Dreyfus Maria S.'s purchase, we observed that on January 4, 2024, Ubben Jeffrey W. granted 2,500 shares, which could signal confidence in the company. On the same day, Powell Dina H. claimed no ownership of stock but was granted 8,000 shares, indicating a new ownership stake. These events suggest a mix of adjustments in holding

    6/20/24 1:39:11 PM ET
    $XOM
    Integrated oil Companies
    Energy